share_log

Iovance Biotherapeutics, Nio, NetEase And Other Big Stocks Moving Lower On Wednesday

Benzinga ·  Dec 27, 2023 12:26

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 80 points on Wednesday.

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) fell sharply during Wednesday's session after the company announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC).

The FDA placed a clinical hold on the IOV-LUN-202 trial on December 22, 2023, in response to a recently reported Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen.
Iovance Biotherapeutics shares dipped 20.4% to $7.07 on Wednesday.

Here are some other big stocks recording gains in today's session.

  • Nukkleus Inc. (NASDAQ:NUKK) shares declined 28.8% to $2.60 after jumping around 11% on Tuesday.

  • GreenTree Hospitality Group Ltd. (NYSE:GHG) fell 10% to $3.69.

  • InnSuites Hospitality Trust (NYSE:IHT) dipped 8.6% to $1.4250.

  • LanzaTech Global, Inc. (NASDAQ:LNZA) fell 7.6% to $5.00.

  • Life Time Group Holdings, Inc. (NYSE:LTH) fell 6.9% to $14.30. On Dec 22, Life Time Group Holdings agreed with company's CFO, Robert Houghton that he will resign as CFO.

  • Cheche Group Inc. (NASDAQ:CCG) fell 6.3% to $6.51.

  • Canopy Growth Corporation (NASDAQ:CGC) declined 6.2% to $5.31.

  • Velocity Financial, Inc. (NYSE:VEL) fell 4.8% to $15.62.

  • The Beauty Health Company (NASDAQ:SKIN) fell 4.8% to $3.0850.

  • NetEase, Inc. (NASDAQ:NTES) fell 4.2% to $88.30 on continued volatility amid regulatory developments in China's gaming sector.

  • NIO Inc. (NYSE:NIO) fell 4.1% to $8.95 after rising more than 10% on Tuesday. Nio stock raced higher to start the week after the company launched its new ET9 sedan at its Nio Day event over the weekend.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment